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Thyroid growth stimulating activity in highly purified IgG-fractions 
of patients with nonimmune thyroid diseases1 
M.D. O e t h i n g e r , B.E. W e n z e l , a n d P.C. S c r i b a 
Department of Medicine, Cell- and Immunobiological Laboratory, Medical University of Lübeck, 
D - 2400 Lübeck, FRG. 
ABSTRACT. Two different proliferation assays 
have been used to measure the proliferative 
Potential of IgG-fractions from 57 patients with 
nontoxic goiter of an iodine-deficient area: primary 
human thyroid epithelial cells (TEC) and the 
thouroughly investigated FRTL-5 cell line. IgG-
fractions from patients with nontoxic goiter 
(n = 30), nontoxic recurrent goiter (n = 8), toxic-
nodular goiter (n = 15) and Carcinoma of the thyroid 
(n = 4) were highly purified on DEAE-Sepharose 
and additionaly Protein A-Sepharose in some 
cases. The two proliferation assays gave contra-
dictory results: primary cultures of human thyroid 
epithelial cells (TEC) could not be stimulated by 
any of the patient's IgG-fractions nor by bTSH. 
The FRTL-5 cells, however, were stimulated with 
10 / /U/ml bTSH by 326% ± 96% (ränge: 222% -
497%, p < 0.001). In one experimental series, 72% 
of all patients exceeded mean + 2 SD of normal 
controls, when the Stimulation index was referred 
to the effect of bTSH (NTG: 77%, Ree. G.: 88%, 
Tox. G.: 53%, Ca. thyroid: 75%). With a different 
method of calculation - Stimulation index referred 
to the basal value - the number of patients above 
mean + 2 SD of normal controls decreased to 30% 
1 Abbreviations used: 
AC-activity, activity of the adenylate-cyclase; bTSH, bovine thyroidea 
stimulating hormone; Ca. thyroid, Carcinoma of thyroid; FRTL-5 cells, 
Fischer's rat thyroid cell line 5; GD, Graves' disease; 3 H-TdR, 3 H-Thym-
idine; IBMX. 3-isobutyl-1-methyl-xanthine; MAB, microsomal antibody; 
NTG, non-toxic goitre; PBS, phosphate buffered saline; Ree. goiter, rec-
urrent goiter; SD, Standard deviation; Sl, Stimulation index; TAB, thyroglo-
bulin antibody; TBII, TSH-binding inhibiting immunoglobulin; TGI, thyroid 
growth stimulating immunoglobulin; Tox. goiter. toxic goiter, TSI. thyroid 
stimulating immunoglobulin. 
Key-words: Non-immune thyroid disease, thyroid growth stimulating an-
tibody (TGI), FRTL-5 cells, human thyroid epithelial cells (TEC). 
Correspondence to. Dr. B.E. Wenzel, Department of Medicine, Cell and 
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Allee 160, D - 2400 Lübeck, FRG. 
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(NTG: 33%, Ree. G.: 12,5%, Tox. G.: 33%, Ca. thy-
roid: 25%). Statistical analysis, however, of results 
of different patient groups compared to the normal 
control group failed to show any significance. 
INTRODUCTION 
When growth stimulating activity on thyroid cells in 
vitro was first described by Drexhage in 1980 (1) 
and ascribed to immunoglobulin G action (TGI), an 
intriguing coneept to explain goiter formation was 
created. TGI has been reported not only in autoim-
mune thyroid diseases such as Graves' disease 
(GD), but also in patients with nontoxic (euthyroid) 
goiter (2-4). This coneept would unify almost all 
thyroid diseases in an autoimmune etiology. The 
existence, however, of this growth stimulating im-
munoglobulin in patients with nonimmune thyroid 
diseases is still a matter of controversy. A variety 
of assay Systems have been applied to measure 
TGI, but results have not been consistent (Table 1). 
This is in part due to different sources of thyroid 
cells and might reflect different growth responses 
in diverse in vitro Systems. Regulation of cell growth 
has been shown to be a highly complex matter in 
both human and animal thyroid cells (14-23). Fur-
thermore, Gärtner showed that the thyroid growth 
stimulating activity of crude IgG-fractions prepared 
by ammonium sulfate preeipitation was due to the 
contamination with epidermal growth factor (EGF) 
and could be abolished by subsequent purification 
with DEAE- and Protein A-Sepharose (24). More-
over, TGI has not yet been convincingly detected 
with assay Systems using human thyroid cells, as 
shown by Wenzel (25). 
Our interest was to reassess the suggested role of 
TGI in nonimmune goitrous patients from an iodine 
deficient area. We used FTRL-5 cells for the mea-
surement of the proliferative potential of IgG-frac-
tions (26). Results in this animal System were com-
pared to a System using human thyroid epithelial 
631 
M.D. Oethinger, B.E. Wenzel, and P.C. Scriba 
cells (TEC) to account for species-specific differ-
ences of growth control. Furthermore we studied 
the Stimulation of the second messenger cAMP in 
a TSI assay. Thereby we looked closely at our 
methods to identify possible pitfalls in the measure-
ment of TGI activity in clinical studies as summar-
ized by Dumont (27). 
MATERIALS AND METHODS 
Patient profile 
IgG-fractions were collected from 57 consecutive 
patients with nonimmune thyroid diseases attending 
the thyroid clinic at the Medical University of Lübeck. 
Diagnosis was based on clinical assessment and 
confirmed by an euthyroid State and the absence 
of TBII. Thirty patients had a nontoxic goiter (NTG), 
8 patients had a nontoxic recurrent goiter (Ree. G.), 
15 had a toxic-nodular goiter (Tox. G.) and 4 pa-
tients suffered from Carcinoma of thyroid (Ca. thy-
roid); 78% of patients were female (n = 46). Age 
ranged from 16-77 yr (mean: 47 yr, median: 50 yr); 
23% were weakly positive for MAB (ränge: 1:1600 
-1:6400), 18% weakly positive for TAB (ränge: 1:160 
- 1:1280). Goiter size was estimated clinically and 
measured sonographically: 47% had WHO grade I, 
40% grade II and 13% grade III with Symptoms due 
to local obstruetion. The iodine-deficiency of the 
region is manifested by a low urinary iodine exere-
tion of 84 l/g Creatinine as compared to 170 /jg 
l /g Creatinine in Sweden (28). 
Control group 
Control sera for the normal control were obtained 
from 11 healthy individuals without evidence of thy-
roid disease, as confirmed by clinical examination, 
estimation of thyroid hormones and the absence of 
thyroid autoantibodies. IgG-fractions were treated 
and assayed individually. The IgG of a patient with 
Graves' disease who was newly diagnosed served 
as positive control (pos. control). She had high titers 
of microsomal, thyroglobulin and TSH-receptor an-
tibodies (89% inhibition of TSH-binding). In addition 
IgG-fractions from 3 patients with active Graves' 
disease and from 5 patients with Graves' disease 
in remission were measured in the TSI assay. 
IgG Preparation 
IgG-fractions were prepared from serum by Single 
step affinity chromatography (DEAE Affi-Gel Blue®) 
and followed by protein A-sepharose chromato-
graphy (Protein A-Sepharose CL-4B®) in some 
cases. 
For DEAE Affi-Gel Blue chromatography 3 ml of 
serum were dialysed against 20 mM phosphate 
buffer (pH 8.0) for 12 h. The serum was applied to 
a column and the IgG-peak eluted with 20 mM 
phosphate buffer. The column was regenerated with 
2 M Guanidine-HCI. Eluated fractions were pooled 
aecording to the protein profile monitored by UV-
absorption at 280 nm and dialyzed against PBS, pH 
7.4, for further 12 h. 
For Protein A-Sepharose a small column was 
packed with 3 ml of swollen gel and equilibrated 
with PBS (pH 7.2). One ml of serum was diluted with 
1 ml of PBS and applied to the column. First all 
serum components except IgG 1, 2 and 4 were 
eluted with PBS. The release of the bound IgG was 
performed by an elution with acetic acid (pH 3.0). 
Table 1 - Summary of the results of in vitro measurements of TGI in the serum of patients with Graves' disease, nontoxic goiter and 
recurrent goiter by different research groups. Percentage of TGl-positive patients are given in brackets. 
Graves 1 disease. Nontoxic goiter Recurrent goiter Authors 
9/11 (82%) 4/10(40%) Drexhage HA. 1982 (5) 
16/43 (37%) 1/40 (3%) 3 /9 (33%) Chiovato L. 1983 (6) 
17/27 (63%) 0 /7 (0%) Valente WA. 1983 (2) 
0 /10 (0%) 0 /10 (0%) Risdall J.E. 1984 (7) 
43/62 (69%) Drexhage H.A. 1986 (8) 
22 /36(61%) Smyth P.P.A. 1986(9) 
51/91 (56%) Rotella C M . 1986(10) 
20 /72 (27%) 10/26 (38%) Schalz H. 1986 (4) 
33 /52 (63%) Halpern A. 1986(11) 
0 /10 (0%) Gärtner R. 1986(12) 
3 /19 (16%) 4 /15 (27%) Goretzki P.E. 1987(13) 
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Eluated fractions were pooled according to the pro-
tein profile. They were neutralized and desalted 
immediately by a second run through a Sephadex 
G-25® column with Tris buffer (pH 7.4). The Protein 
A-Sepharose column was regenerated by elution 
with Tris buffer, sodium acetate and reequilibrated 
with PBS. 
Finally IgG fractions were concentrated by dry di-
alysis against Polyethylenglycol (MW 20,000) and 
IgG content was measured by radial immunodiffu-
sion using a commercially available kit. They were 
stored in aliquots in liquid nitrogen until use. Att ime 
of experiment all IgG were diluted in assay medium 
to a Standard concentration of 0.1 mg/ml and finally 
sterilized by passage through a Millipore 22-//m 
filter. This method of purification yielded a highly 
purified IgGs as was demonstrated by immunoe-
lectrophoresis studies. 
FRTL-5 cells 
Stock culture: FRTL-5 cells were obtained from A. 
Pinchera, Pisa. They are a continuously growing, 
expanded normal rat-thyroid cell strain derived from 
the fisher rat thyroid cell line, which is dependent 
on TSH. The cells have been in culture in our 
laboratory since 1985 and still exhibit the charac-
teristie growth pattern of FRTL-5 cells: withdrawal 
of TSH results in a resting phase without evidence 
of cell damage. Proliferation is restored upon re-
addition of TSH. Cells are cultured according to the 
methods of Ambesi-Impiombato (26). Briefly, cells 
are grown in a humidified atmosphere of 5% 
C 0 2 / 9 5 % air at 37 C in Coon's modified F-12 me-
dium supplemented with: 5% calf serum, glutamin 
(2 mmol/l), steptomycin-penicillin (100 mg/1-10 5 
U/l), 33 ml/ l NaHCC 3 - (7.4%), insulin (10 / /g/ l ) 
cortisol (0,4 ywg/l), transferrin (5/ig/l), glycyl-L-his-
tidyl-L-lysin acetat (10 ng/l), somatostatin (10 ng/l) 
("5H-culture medium) and 1 mU/ml bTSH (6H-
culture medium). They are seeded into culture flasks 
(4 x 10 6 cells/flask) and split weekly in a ratio of 1:3 
(approximate doubling time: 30 h). Medium is 
changed twice weekly. On this occasion morphol-
ogy of cells is assessed. In regulär intervals the 
medium is checked for contaminations with myco-
plasma. 
For the proliferation assay FRTL-5 cells were 
seeded into 96-well flat bottom microtiter plates 
(2 x 10 4 cells/well), for the TSI assay into 24-well 
plates (2 x 10 5 cells/well). They were grown in 6H-
medium for 3 to 5 days (80%-confluency), when 
they were switched to 5H-medium and maintained 
in this resting phase for 7 to 10 days. 
Human thyroid epithelial cells (TEC) 
Short term cultures of TEC were established from 
thyroid tissue obtained at Operation from patients 
with GD or NTG. Cells were cultured as previoulsy 
described (25, 29). In brief, thyroid tissue was 
minced, washed and digested enzymatically with 
Dispase II® (2.4 U/ml) two times for 90 min at 37 
C. Cells were washed, separated from debris and 
erythrocytes by density centrifugation, washed again 
and plated in Iscove medium containing the 5H-
mixture described above, glutamine (2 mmol/l), an-
tibiotics and 2.5% fetal calf serum ("Iscove culture 
medium"). 
For the proliferation assay TEC were either seeded 
into 96-well plates (5 x 10 4 cells/well) to obtain 
primary cultures or grown in culture flasks first and 
passaged once or twice before seeded into 96-well 
plates. Cells adhered to the flat bottom in semifol-
licle-like structures ("domes") displaying "right-side-
out" polarity. The differentiated function of TEC was 
verified by their ability to secrete thyroglobulin. After 
3 days cultures were used for experiments. For the 
TSI assay 10 5 cells/well were seeded into 24-well 
plates and used after 3 days. 
Proliferation assay 
Assay protocols for both cell Systems, FRTL-5 cells 
and TEC, were comparable. At time of experiment 
cells were washed and medium was replaced by 
medium + dissolved stimulators ("5H culture medi-
um" for FRTL-5 cells and "Iscove culture medium" 
for TEC as described above). Incubations were 
carried out in quadruplicates (final volume 200 
/yl/well for both Systems). In preliminary dose-finding 
experiments FRTL-5 cells were incubated with dif-
ferent doses of bTSH (ränge: 0.1/AJ/ml - 1000 
mU/ml) or IgG from the positive control (ränge: 
0. 05 mg/ml - 2.0 mg/ml). In further experiments 
FRTL-5 cells on each plate were incubated with 
medium only (basal value), with bTSH (0.01 mU/ml) 
or other stimulators such as EGF or IGF-1. All IgGs, 
1. e. pos. IgG, control IgG and unknown IgG samples, 
were used at a final concentration of 0.1 mg/ml. 
10 fj\ of 3H-Thymidine was added to each well to 
a final concentration of 0.5 //Ci/well. After 72 h of 
incubation cultures were trypsinized and harvested 
with use of a semiautomatic cell harvester (washing 
sequence: distilled water, TCA and alcohol). Ra-
dioactivity incorporated into DNA of cells (rinsed 
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onto cellulose acetate filter disks) was counted in 
a liquid scintillation counter. The proliferative effect 
of bTSH or IgG was routinely evaluated by calcu-
lating a Stimulation index I (Sl) as follows: 
cpm (sample)/ cpm (basal) x 100 = Sl in %. 
With a different calculation method the IgG-effect 
on the 3H-Thymidine incorporation into cells was 
referred to the bTSH effect and a further Stimulation 
index II was calculated as follows: 
cpm (sample)/ cpm (bTSH) x 100 = Sl in %. 
TSI assay 
For the TSI assay the stimulators (bTSH, IgG) were 
dissolved in "5H culture medium" for FRTL-5 cells 
and "Iscove culture medium" for TEC, both supple-
mented with 0.5 mmol/l IBMX. IgGs were measured 
at a Standard concentration of 0.1 mg/ml. Incuba-
tions were performed in duplicate wells (200 
/i l /well). After 24 h at 37 C the supernatant was 
taken of the cells. Twenty jj\ of 1 M Hepes-buffer 
was added to the supernatant and samples were 
stored at -70 C. For the time course the supernat-
ants were taken of the cells at time intervals indi-
cated. Extracellular cAMP content was measured 
in duplicates with a commercially available com-
petitive protein binding assay kit using 8-(3H) cAMP 
as tracer (detection ränge: 0.2-16 pmol cAMP/50/yl; 
between-assay Variation: 7.3%). Separation of pro-
tein-bound from free cAMP was performed by char-
coal absorption. An aliquot of the protein-bound 
fraction was counted in a liquid scintillation counter. 
Results were expressed as pmol cAMP / well (mean 
of duplicate wells) or Stimulation indices were cal-
culated as pmol cAMP (sample)/ pmol cAMP (ba-
sal) x 100= Sl i n%. 
Statistical evaluation 
Results of normal controls were checked for normal 
distribution, which proved to be the case for both 
proliferation and TSI assay. The distribution of 
TGI and TSI activities of control and patient groups 
was evaluated by the U-test of Mann and Whitney 
for unpaired data and the Wilcoxon rank test for 
paired data. The level of significance was chosen 
a s p < 0 . 0 5 . 
Reagents 
TRAK-assay was purchased form Henning Berlin, 
FRG. Deae Affi-Gel Blue was obtained from Bio-
Rad Laboratories GmbH, München FRG, and Pro-
tein A Sepharose CL-4B from Pharmacia Labora-
tories, Uppsala, Sweden. LC-Partigen-IgG and pro-
tein Standard-Serum LC-V were from the Behring 
Insituts, Frankfurt, FRG. Dispase II was from Boeh-
ringer, Mannheim, FRG. Coon's modified F-12 me-
dium was purchased from Gibco, Paisley, UK. In-
sulin was obtained from Hoechst, Frankfurt, FRG, 
bTSH (Thyreostimulin) from Organon, München, 
FRG. Somatostatin, hydrocortisone, transferrin, glyc-
yl-histidyl-l-lysin-acetate and IBMX were all pur-
chased from Sigma Chemie GmbH, Deisenhofen, 
FRG. Iscove medium, IGF-1 and calf serum were 
from Biochrom KG, Berlin, FRG. EGF was pur-
chased from Genzyme, München, FRG. (Methyl-
3H)-Thymidine was obtained from New England Nu-
clear, NEN Research Products, Dreieich, FRG. The 
cAMP protein binding assay kit was purchased from 
Amersham Buchler, Braunschweig, FRG. A semi-
automatic cell harvester, Multimash 2000 AM 74, 
from Dynatech, Denkendorf, FRG and a LKB Wallac 
1219 Rackbeta liquid scintillation counter from LKB 
Instrument GmbH, Gräfelfing, FRG were used. 
RESULTS 
Standardization of the proliferation assay 
In an initial experiment the dose response curve of 
bTSH-deprived FRTL-5 cells to re-addition of bTSH 
was established. As shown in Figure 1 A, FRTL-5 
400 
c 
iZ 300 
CO 
B 
a 
3 
I 
I 
CO 
200 -
100 
-3 -2 
log bTSH concentrat ion (mU/ml) 
Fig. 1 (A) - Dose response curve of FRTL-5 cells in 96-well 
plates stimulated with bTSH. Results are expressed as Sl in % 
of basal Mean + SD of6 experiments are depicted. 
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Stimulation with 10 / /U/ml bTSH resulted in a sig-
nificantly increased radioisotope incorporation: the 
Sl (compared to the basal value = 100%) was about 
300%. The dose of 1 mU/ml bTSH gave a maximal 
response, a plateau was reached at higher con-
centrations. Hence the submaximal dose of 10 
/ /U/ml bTSH was used as the TSH control on each 
plate. 
In a similar way the dose-response curve of FRTL-
5 cells to human IgG-fractions was established. 
The positive control (pos. control) stimulated 3 H -
TdR incorporation maximal at a concentration of 
0.12 mg/ml (Fig. 1B). It was a less potent stimulator 
at 0.05 mg/ml. Concentrations exceeding 1 mg/ml, 
however, resulted in a variable degree of cell dam-
age and reduced radioisotope incorporation. In con-
trast, IgG-fractions of healthy individuals (control 
IgG) did not show this bell-shaped dose response 
curve: 3H-TdR incorporation was only slightly in-
creased compared to basal incorporation of resting 
cells at all concentrations investigated (data not 
shown). Thus the concentration of 0.1 mg/ml was 
adopted as Standard condition for all subsequent 
studies described in this report. 
Furthemore the possible influence of the IgG-pur-
3 6 0 -
5 0 -
O-l , , , , , 
0 0,1 0,2 0.3 0,4 0,5 0,6 
IgG (mg/ml) 
Fig. 1 (B) - Dose reponse curve of FRTL-5 cells in 96-well plates 
stimulated with IgG from a patient with active Graves' disease. 
Results are expressed as Sl in % of basal. A typicaf curve is 
shown. 
ification process on the FRTL-5 cell response was 
investigated. No significant difference was found 
between IgG-fractions purified with DEAE Affi-Gel 
Blue chromatography as compared to Protein A-
Sepharose. Analysis of possible contaminations in 
both IgG-preparations showed only traces of TSH 
( < 0.22 mU/l) , whereas TBII content was fully pre-
served (e.g. serum: 29% inhibition of TSH-binding, 
following DEAE Affi- Gel Blue chromatography: 37%, 
following Protein A-Sepharose chromatography: 
28%). 
In order to establish a normal ränge, we measured 
the IgG-fractions of 11 healthy controls individually 
at the beginning and at the end of our main exper-
imental series, i.e. using different subcultures of 
cells. The Sl ranged from 109% to 187% with re-
spect to control cultures (basal value). Results 
showed a Standard distribution (Fig. 2): mean (142%) 
500 
0 1 I I 1 I 
Control TSH 0.01 Pos. mean + 
IgG mU/ml IgG 2or3SD 
Fig. 2 - Left: Sl of IgG-fractions of normal control, measured in 
two separate assays. Right: Sl of controls during one experimental 
series (n = 13 plates measured in 5 separate assays). Each 
symbol represents the result of bTSH and positive IgG on one 
plate. 
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and SD (21%) was calculated. We defined the nor-
male ränge as mean + 2 SD with a cut-off line of 
184% (95%-percentile), and also a confidence 
ränge as mean + 3 SD (99.7%-percentile): Cut-off 
line was now205%. 
The results of the controls on each 96-well plate 
were used to assess the reproducibility of our pro-
liferation assay. Table 2 summarizes ränge, mean, 
intra-and inter assay Variation of repetitive results 
of two given IgG-fractions and bTSH in the Standard 
concentration of 0.01 mU/ml during one experi-
mental series. This series concluded thirteen 96-
well plates measured in five separate assays, i.e. 
using five different FRTL-5 cell preparations, within 
six weeks. The intraassay Variation (coefficient of 
Variation: 8% to 13%) was low, whilst inter assay 
Variation was considerably high with a coefficient of 
Variation of almost 30%. 
Application of the same standardization protocol to 
TEC proved to be impossible. We failed to induce 
a growth response of TEC towards bTSH (0.01 - 1 0 
mU/ml) or to other growth stimulators such as EGF 
(10 ng/ml) or IGF-1 (10 ng/ml). None of our IgG-
fractions resulted in any significant increase of 3 H -
TdR incorporation (e.g. medium: 1410 cpm/well , 
pos, IgG, 1717 cpm/well). We did not achieve pro-
liferation by use of different sources of thyroid tissue 
nor by subculturing cells prior to experiments. In 
contrast, the same batches of TEC were responsive 
to bTSH and IgG-fractions in respect to AC-activity 
measured as increase of extracellular cAMP in the 
TSI-assay (Fig. 3B, Table 3). 
Standardization of the TSI assay 
The Stimulation of FRTL-5 cells grown in 24-well 
Table 2 - Range, mean and median of Stimulation indices (in %) 
during one experimental series (n = 13 plates measured in 5 
separate assays). 
*Average of coefficients of Variation of samples on one plate 
** Coefficient of Variation of between-assay-Variation # p < 0.001 
plates resulted in an increase of extracellular cAMP 
detectable after as little as 30 min. Stimulation of 
the AC-activity by bTSH was dose-dependent in 
Contr. IgG pos. IgG bTSH 
Range (Sl) 90 - 147* 205 - 408# 222 - 497 
Mean (Sl) 113 266 326 
Median (Sl) 110 267 299 
Intraassay 
Variation of S l* 1 1 % 13% 8% 
Interassay 
Variation of S l * * 15% 29% 29% 
0 0.001 0.01 0.1 1 10 100 1000 
bTSH concentrat ion (mU/ml) 
Fig. 3 (A) - Dose-response curve of FRTL-5 cells stimulated. with 
bTSH as measured by the increase of extracellular cAMP after 
4 h and 24 h of incubation. 
200 
< 
ü 
O 
E 
CL 
150 
100 
50 
0.01 0.1 1 10 
bTSH in m U / m l 
Fig. 3 (B) - Dose-response curve of human TEC stimulated with 
bTSH as measured by the increase of extracellular cAMP after 
24 h of incubation. 
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Table 3 - Standardization of the TSI assays with FRTL-5 cells 
and TEC in 24-well plates. Stimulation of AC-activity by IgG-
fractions of normal control, positive control and unknown samples 
from patients with active GD, GD in remission and non-immune 
thyroid diseases. Results are given in pmol cAMP/well (mean 
of duplicate) or expressed as Sl in % of basal 
FRTL-5 cells TEC 
• Controls 
Basal value 
- Range (pmol cAMP/well) 
- Mean ± SD (pmol cAMP/well) 
Control IgG (n = 11) 
- Range (pmol cAMP/well) 
- Mean ± SD (pmol cAMP/well) 
- Mean ± SD (as Sl in %) 
• Definition of normal ränge 
- Mean + 2 SD (in pmol cAMP/well) 
- Mean + 2 SD (as Sl in %) 
8.1-9.6 
8.9 ± 1.8 
5.0-9.2 
6.6 ± 1.8 
75% ± 20% 
10.2 
115% 
• Patient samples (ränge as Sl in % of basal) 
Active Graves' disease (n = 4) 44%-511 % 
Graves' disease in remission (n = 5) 33%-100% 
Nontoxic goiter (n = 16) 50%-110% 
1.0-1.4 
1.2 ±0 .2 
0.8-1.6 
1.3 + 0.27 
108% ± 2 3 % 
1.84 
154% 
117%-433% 
100%-134% 
100%-133% 
5 cells 0.5 mU/ml bTSH yielded a maximal re-
sponse. IgG-fractions exhibited a slower and less 
pronounced effect than. bTSH, as shown in the 
time-course in Figure 4. IgG-fractions from the con-
trol group failed to stimulate AC-activity significantly. 
From these results a confidence ränge was calcu-
lated as given in Table 3. 
Patient studies 
All 57 samples were measured in one experimental 
series as described above: all samples were pro-
cessed on thirteen plates in five separate assays 
within six weeks. The results of the patients are 
given graphically in Figure 5: each symbol repres-
ents the result of one patient within his group of 
diagnosis. The percentages of patients above the 
cutt-off line of the normal ränge are: NTG = 33%, 
Ree. G. = 12.5%, Tox. G. = 33% and Ca. thyroid = 
25%. Marked differences of results can be achieved 
when the definition of the confidence ränge is app-
lied. The percentages decrease to NTG = 20%, Tox 
G. =-20% and even Ca. thyroid = 0%. 
FRTL-5 cells (Fig. 3A) as well as TEC (Fig. 3B). It 
seemed from these few experiments that TEC re-
sponse did not result in a plateau, whereas in FRTL-
< 
ü 
o 
E 
CL 
80 
70 
== 60 
5 0 
4 0 
3 0 
0.1 mU/ml TSH 
Incubation time in hours 
Fig. 4 - Time course of adenyfate-cyclase activation of FRTL-
5 cells by bTSH and different IgG-fractions as measured by the 
increase of extracellular cAMP. Standard concentration of IgG 
was 0.1 mg/ml. 
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Fig. 5 - 3H-Thymidine incorporation of FRTL-5 cells incubated 
with IgG from patients with nonimmune goitrous disease: NTG 
= nontoxic goiter (n= 30), Ree. G. = recurrent goiter (n = 8), Tox. 
G. = toxic-nodular goiter (n = 15), Ca. thyroid = Carcinoma of 
thyroid (n = 4). Cut-off line was defined as mean of normal 
controls + 2 SD (normal ränge: -) and mean of normal control 
-f-3SD (confidence ränge: -). 
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The next step was to alter the method of evaluation 
completely. Results of samples were expressed as 
percent of bTSH-effect and the Stimulation index II 
was calculated as described in Materials and Me-
thods. Although the same raw data were used as 
before, far higher frequencies of "TGl-positive" IgGs 
can be achieved by this procedure (Fig. 6). Percen-
tages exceeding mean + 3 SD are now: NTG = 
73%, Ree. G. = 88%, Tox. G. = 47% and Ca. thyroid 
= 75%; these figures are still higher by looking at 
samples exceeding mean + 2 SD: NTG = 77% and 
Tox. G. - 53%. 
In all cases, however, Statistical analysis of the 
distribution of either patient group showed no differ-
ence from the normal control group. In contrast, the 
response of the pos. IgG did differ significantly from 
the normal control group ( p < 0.001). Likewise Sta-
tistical analysis failed to show any correlation be-
tween results of Single patients in the proliferation 
120 
s 
o 
C/5 60 
4> 
s 
20 
Y 
4 
• -
o 
oo 
Cootr. Pos. 
1«G IgG 
NTG RecG. Tox-G. C*.tby. 
Fig. 6 - 3H-Thymidine uptake of FRTL-5 cells incubated with IgG 
from patients with non-immune goitrous thyroid diseases. Sl is 
now related to the TSH-effect in the proliferation assay as des-
cribed in Materials and Methods (normal ränge: confidence 
ränge ). 
assay and clinical data such as goiter size, level of 
autoantibodies, therapy or onset of disease. 
Finally TSI was measured in the bioassay described 
above. None of the patients with nonimmune goi-
trous disease were found to be TSI-positive. A small 
group of Graves' disease patients with high titers of 
TBII were measured as control group in this addi-
tional assay: only patients with active disease (hy-
perthyroid State) could stimulate the AC-activity. 
The TGl-positive IgG-fraction was also TSI-positive 
(FRTL-5: Sl = 211 % of basal, TEC: Sl = 433%). Two 
IgG-fractions from patients with Graves' disease 
were found to be TSI-positive without stimulating 
the proliferation of FRTL-5 cells (Sl in the TSI assay 
with FRTL-5 cells: 144% and 511% respectively, Sl 
in the proliferation assay with FRTL-5 cells: 129% 
and 118% respectively). The contrary, however, 
TGl-positive but TSI-negative IgG-fractions were 
not encountered in this limited study. Results ob-
tained in the TSI-assay using human TEC confirmed 
the results of the FRTL-5 cell assay. 
DISCUSSION 
In our study we intended to establish a reliable 
assay System to assess proliferative potential of 
human IgG-fractions from patients with nonimmune 
goitrous diseases. In contrast to most studies we 
used highly purified IgG-fractions which were virtu-
ally free of potientially contaminating growth factors. 
We could confirm that this way of purification does 
not abolish biological activity of IgG, since IgG-
fractions from GD-patients were still capable of 
stimulating the adenylate-cyclase activity of FRTL-
5 cells as well as TEC. Our positive control, too, 
was able to stimulate 3H-Thymidine incorporation 
of FRTL-5 cells to a degree which was comparable 
to the effect of 10 / /U/ml bTSH. 
We could clearly demonstrate that the method of 
data calculation alters the outcome of the study. 
Using the same raw data but changing the reference 
point, we got 0 /4 TGl-positive patients with Carci-
noma of the thyroid (Fig. 5) as well as 3/4 (Fig. 6)! 
Further studies showed that TSH - and IgG-effect 
have different kinetics (Fig. 4) and TSH should there-
fore not be used as reference. This is very consist-
ent with a study of Bidey (30). In a TSI-assay using 
primary monolayer cultures of human thyroid cells 
3 of 23 untreated patients with active Graves' dis-
ease were shown to be TSI-negative when their 
IgG was initially tested. With a different cell prep-
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aration these IgG-fractions induced a significant Stim-
ulation of intracellular cAMP accumulation. TSH, 
however, stimulated the AC-activity in both cell prep-
arations by more than 300% of basal. Bidey con-
cluded that there may be no consistent correlation 
between TSH and TSI-responsiveness. 
Another source of divergent results of patient stud-
ies is the need to draw a reliable cut-off line to label 
IgG-fractions as being TGl-negative or TGl-positive. 
In most studies the Standard definition of "upper 
limit of normal ränge" is employed, i.e. mean + 2 
SD, but Goretzki (13) f.ex. uses 99.9% cut-off line 
(mean + 5 SD). We decided to apply two different 
operational definitions (mean + 2 SD, mean + 3 SD) 
to illustrate the effect on the results of our study. 
Further more, there are different ways of measuring 
normal control IgG-fractions: in many studies IgG-
fractions are pooled prior to incubation or even 
prior to purification procedures. This leads to idio-
type-antiidiotype complexing and makes biological 
activities incompatible (33). In consequence an IgG-
preparation is obtained with a comparably narrow 
ränge of results in consecutive proliferation assays 
which itself results in a relatively low upper limit of 
normal ränge and hence a high proportion of "TGl-
positive" samples. 
Furthermore, looking at quality criteria of an exper-
imental system like intra- and interassay Variation 
our FRTL-5 cell strain unfortunately showed a high 
variability between subcultures even within one 
experimental series, expressed by an inter assay 
Variation of 29%. Although most studies do n'ot quote 
the figures of between-assay-variability, it is well 
known to be a problem. Bidey and Marshall looked 
at this general problem of bioassays. They evaluated 
both human thyroid cells in primary culture (30, 31), 
and FRTL-5 cells (32) with a particular interest in 
precision characteristics. The interassay Variation 
of the cAMP-response of seven FRTL-5 subcultures 
to TSH was 25%. This is similar to our finding in 14 
FRTL-5 subcultures (29%). This result was consi-
dered to be in marked contrast to equivalent data 
for primary cultures of human thyroid cells, when 
an interassay Variation of over 70% was observed. 
There are a number of theoretical reasons, why this 
high variability should exist: 
— IgG-fractions could gradually loose biological 
activity. This is unlikely, because there was no sys-
tematic decline in the proliferative potential of pos-
itive and normal control during our experimental 
series. 
— Sl of cells show a mirror-image dependency on 
basal 3H-Thymidine incorporation (not published). 
This basal incorporation itself could be influenced 
by a different number of cells per well. This is 
unlikely, because high precision pipettes are used 
in laboratories. We could not, however, rule this out, 
since our method with use of a semiautomatic cell 
harvester makes DNA assays or cell counting im-
possible. 
— The FRTL-5 cell strain is a mixture of different 
subcultures of cells. it is known, that long term 
cultures in vitro change their genotype or de-dif-
ferentiate (15). This could lead to differences in 
receptor density for TSH or IgG or in different cell 
metabolism rates thus influencing basal 3 H-Thym-
idine incorporation. 
We favor the latter, but did not look at this topic in 
detail. Further studies need to be conducted to look 
closer at the cells on a biochemical level. 
The application of FRTL-5 cells in proliferation as-
says is further limited by what looks like species-
specific control mechanism of proliferation. We con-
firmed once again (25, 29, 34) that TSH is not a 
growth factor for human TEC in monolayer culture. 
Recent studies suggest an involvement of EGF, 
insulin and insulin-like growth factor I (34), but the 
exact mechanisms of proliferation control are not 
yet known (35). Our human cell System was not 
responsive to EGF which is in contrast to other 
studies (13,36). One explanation could be that EGF 
was unable to bind to its receptor since human TEC 
grow as a monolayer. Westemark, however, dem-
onstrated recently that human thyroid cells possess 
EGF-receptors which were found to be located 
asymmetrically at the basal cell surface (35). Roger 
investigated the influence of different serum content 
of culture media on responsiveness of cells towards 
TSH and EGF (36). Proliferation of human thyroid 
cells could be stimulated by TSH only when cells 
were grown in insulin-supplemented low serum (1 %) 
or even under nonphysiological serum-free condi-
tions. 
The growth regulation in FRTL-5 cells is obviously 
different from human thyroid cells in vitro and results 
may lead to erroneous conclusions (27): bTSH stim-
ulates growth of FRTL-5 cells and cAMP is at least 
one mediator for that action. In human TEC, bTSH 
does not influence growth but increases activity of 
the adenylate-cyclase (25). Hence, TSI could be a 
growth promotor in the FRTL-5 cell assay acting via 
increased production of cAMP, whilst this TSI would 
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only exhibit Stimulation of function, but not of growth 
in the human TEC assay. 
In summary we conclude that the proliferation assay 
can be readily used to detect substances with a 
pronounced stimulatory effect on FRTL-5 cells, e.g. 
bTSH or GD-lgG. Its use, however, for substances 
with a rather low potential to stimulate FRTL-5 cell 
proliferation as would be expected in patients with 
non immune thyroid disease, is limited due to high 
inter assay Variation. This could only be circumvent-
ed by multiple measurements using different sub-
cultures of cells and by increasing numbers of con-
trols and patients. Standardization of the proliferation 
assay would help to make results of different labor-
atories comparable. We conclude that only IgG-
fractions with a consistent growth stimulating effect 
should in future be labelled 'TGl-positive". 
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